115 related articles for article (PubMed ID: 24608197)
1. Gene expression and prognosis in bladder cancer--real progress? Editorial on 'S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy'.
Symanowski JT; Kim ES
Ann Oncol; 2014 May; 25(5):919-20. PubMed ID: 24608197
[No Abstract] [Full Text] [Related]
2. S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy.
Kim WT; Kim J; Yan C; Jeong P; Choi SY; Lee OJ; Chae YB; Yun SJ; Lee SC; Kim WJ
Ann Oncol; 2014 May; 25(5):974-9. PubMed ID: 24631944
[TBL] [Abstract][Full Text] [Related]
3. Prediction of recurrence in low and intermediate risk non-muscle invasive bladder cancer by real-time quantitative PCR analysis: cDNA microarray results.
Mares J; Szakacsova M; Soukup V; Duskova J; Horinek A; Babjuk M
Neoplasma; 2013; 60(3):295-301. PubMed ID: 23452234
[TBL] [Abstract][Full Text] [Related]
4. Comparison of mRNA, Protein, and Urinary Nucleic Acid Levels of S100A8 and S100A9 between Prostate Cancer and BPH.
Yun SJ; Yan C; Jeong P; Kang HW; Kim YH; Kim EA; Lee OJ; Kim WT; Moon SK; Kim IY; Choi YH; Kim WJ
Ann Surg Oncol; 2015 Jul; 22(7):2439-45. PubMed ID: 25348783
[TBL] [Abstract][Full Text] [Related]
5. Editorial comment from Dr Miyata to Functional polymorphisms in the matrix metalloproteinase genes and their association with bladder cancer risk and recurrence: a mini-review.
Miyata Y
Int J Urol; 2014 Aug; 21(8):754. PubMed ID: 24661273
[No Abstract] [Full Text] [Related]
6. Editorial comment from Dr Szarvas to Functional polymorphisms in the matrix metalloproteinase genes and their association with bladder cancer risk and recurrence: a mini-review.
Szarvas T
Int J Urol; 2014 Aug; 21(8):753. PubMed ID: 24635598
[No Abstract] [Full Text] [Related]
7. The role of oncostatin M receptor gene polymorphisms in bladder cancer.
Deng S; He SY; Zhao P; Zhang P
World J Surg Oncol; 2019 Feb; 17(1):30. PubMed ID: 30755233
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of Epidermal Growth Factor Receptor (EGFR) and HER-2 in Bladder Carcinoma and Its Association with Patients' Clinical Features.
Li W; Wang Y; Tan S; Rao Q; Zhu T; Huang G; Li Z; Liu G
Med Sci Monit; 2018 Oct; 24():7178-7185. PubMed ID: 30296252
[TBL] [Abstract][Full Text] [Related]
9. Expression signature defined by FOXM1-CCNB1 activation predicts disease recurrence in non-muscle-invasive bladder cancer.
Kim SK; Roh YG; Park K; Kang TH; Kim WJ; Lee JS; Leem SH; Chu IS
Clin Cancer Res; 2014 Jun; 20(12):3233-43. PubMed ID: 24714775
[TBL] [Abstract][Full Text] [Related]
10. Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder.
Wright C; Mellon K; Johnston P; Lane DP; Harris AL; Horne CH; Neal DE
Br J Cancer; 1991 Jun; 63(6):967-70. PubMed ID: 1712624
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor status predicts local response to radical radiotherapy in muscle-invasive bladder cancer.
Colquhoun AJ; Sundar S; Rajjayabun PH; Griffiths TR; Symonds RP; Mellon JK
Clin Oncol (R Coll Radiol); 2006 Nov; 18(9):702-9. PubMed ID: 17100158
[TBL] [Abstract][Full Text] [Related]
12. A DDX31/Mutant-p53/EGFR Axis Promotes Multistep Progression of Muscle-Invasive Bladder Cancer.
Daizumoto K; Yoshimaru T; Matsushita Y; Fukawa T; Uehara H; Ono M; Komatsu M; Kanayama HO; Katagiri T
Cancer Res; 2018 May; 78(9):2233-2247. PubMed ID: 29440146
[TBL] [Abstract][Full Text] [Related]
13. Significance of S100A8, S100A9 and calprotectin levels in bladder cancer.
Yasar O; Akcay T; Obek C; Turegun FA
Scand J Clin Lab Invest; 2017 Oct; 77(6):437-441. PubMed ID: 28609200
[TBL] [Abstract][Full Text] [Related]
14. Elevated S100A9 expression in tumor stroma functions as an early recurrence marker for early-stage oral cancer patients through increased tumor cell invasion, angiogenesis, macrophage recruitment and interleukin-6 production.
Fang WY; Chen YW; Hsiao JR; Liu CS; Kuo YZ; Wang YC; Chang KC; Tsai ST; Chang MZ; Lin SH; Wu LW
Oncotarget; 2015 Sep; 6(29):28401-24. PubMed ID: 26315114
[TBL] [Abstract][Full Text] [Related]
15. C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value.
Mellon JK; Lunec J; Wright C; Horne CH; Kelly P; Neal DE
J Urol; 1996 Jan; 155(1):321-6. PubMed ID: 7490879
[TBL] [Abstract][Full Text] [Related]
16. Molecular prognostic factors in bladder cancer.
Vet JA; Debruyne FM; Schalken JA
World J Urol; 1994; 12(2):84-8. PubMed ID: 7916239
[TBL] [Abstract][Full Text] [Related]
17. HMOX1 is an important prognostic indicator of nonmuscle invasive bladder cancer recurrence and progression.
Yim MS; Ha YS; Kim IY; Yun SJ; Choi YH; Kim WJ
J Urol; 2011 Feb; 185(2):701-5. PubMed ID: 21168882
[TBL] [Abstract][Full Text] [Related]
18. FOXM1 predicts disease progression in non-muscle invasive bladder cancer.
Rinaldetti S; Wirtz R; Worst TS; Hartmann A; Breyer J; Dyrskjot L; Erben P
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1701-1709. PubMed ID: 29959570
[TBL] [Abstract][Full Text] [Related]
19. Pattern of somatostatin receptors expression in normal and bladder cancer tissue samples.
Karavitakis M; Msaouel P; Michalopoulos V; Koutsilieris M
Anticancer Res; 2014 Jun; 34(6):2937-42. PubMed ID: 24922657
[TBL] [Abstract][Full Text] [Related]
20. Novel variants in MLL confer to bladder cancer recurrence identified by whole-exome sequencing.
Wu S; Yang Z; Ye R; An D; Li C; Wang Y; Wang Y; Huang Y; Liu H; Li F; He L; Sun D; Yu Y; Li Q; Huang P; Zhang M; Zhao X; Bi T; Zhuang X; Zhang L; Lu J; Sun X; Zhou F; Liu C; Yang G; Hou Y; Fan Z; Cai Z
Oncotarget; 2016 Jan; 7(3):2629-45. PubMed ID: 26625313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
